Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research ; volume:15 ; number:1 ; day:1 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
Discover oncology ; 15, Heft 1 (1.8.2024), 1-11, 12.2024
- Urheber
-
Meng, Yuan
Wang, Xuerui
Yang, Jie
Zhu, Meiying
Yu, Minghui
Li, Longhui
Liang, Yangyueying
Kong, Fanming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12672-024-01171-1
- URN
-
urn:nbn:de:101:1-2410250907339.762078529703
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meng, Yuan
- Wang, Xuerui
- Yang, Jie
- Zhu, Meiying
- Yu, Minghui
- Li, Longhui
- Liang, Yangyueying
- Kong, Fanming
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Investigating processes and impacts of climate change on seawater intrusion in a coastal aquifer
Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Investigating processes and impacts of climate change on seawater intrusion in a coastal aquifer
Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Investigating processes and impacts of climate change on seawater intrusion in a coastal aquifer
Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy